Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
Newly diagnosed AML (WHO 2022 classification or ICC 2022 classification) [+5]
Progression or relapse after induction standard HMAs + Venetoclax therapy [+6]